Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
|Articles|April 17, 2020
Helping Patients and the Public Endure the Pandemic
Author(s)Allen Frances, MD
Allen Frances, MD, delivers a powerful message for mental health professionals to help them navigate the COVID-19 pandemic.
Advertisement
Allen Frances, MD, delivers a powerful message for mental health professionals about the impact of the COVID-19 pandemic on mentally ill patients, clinicians, and the health care system. He offers solutions that may help you navigate these uncertain times.
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
5